Cardiff Oncology Reports Results for Onvansertib in P-II Trial for the Treatment of Colorectal Cancer
Shots:
- The P-II (ONSEMBLE) clinical trial evaluates the safety & efficacy of Onvansertib as 2L treatment in patients (n=23) with RAS-mutated mCRC enrolled under 3 arms incl. FOLFIRI+bev (SoC) alone (Arm 1) or onvansertib (20mg, Arm 2) or (30mg, Arm 3) + FOLFIRI+bev. Additionally, 57% of the evaluable patients remain enrolled at data cutoff date
- The results from the study depicted an ORR of 0%, 13%, or 14% along with 2 partial responses which were confirmed by patients’ subsequent scans
- Earlier in Aug 2023, following the FDA’s suggestion, the trial was discontinued by the company as a step to focus on the clinical evaluation of a 1L treatment for RAS-mutated mCRC
Ref: Cardiff Oncology | Image: Cardiff Oncology
Related News:- Mainz Biomed Collaborates with Liquid Biosciences to Develop AI Enables Screening Tests for Colorectal Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
